NCT01551888 - Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Aclidinium/formoterol 400/12μg

Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler

DRUG

Formoterol

Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®

Trial Locations (1)

29303

Forest Investigative Site 001, Spartanburg